Arturo Molina Md sold $1.4M of PTGX
Chief Medical Officer at Protagonist Therapeutics, Inc. 31,529 shares at an average of $44.86, traded Nov 26, 2024, filed Nov 27, 2024.
Score components
- +15RoleOfficer
- +25Trade size$1.4M at market
- +20Share of holdings soldSold 61% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -13.3%, 3m -19.6%, 6m +1.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-123809, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 26, 2024 | MOption exercise Common Stock | +5,529 | $8.04 | $44k | 51,973 | Nov 27, 2024 |
| Nov 26, 2024 | SOpen-market sale Common Stock | -5,529 | $45.60 | $252k | 46,444 | Nov 27, 2024 |
| Nov 27, 2024 | MOption exercise Common Stock | +10,000 | $8.04 | $80k | 56,444 | Nov 27, 2024 |
| Nov 27, 2024 | SOpen-market sale Common Stock | -10,000 | $44.50 | $445k | 46,444 | Nov 27, 2024 |
| Nov 27, 2024 | MOption exercise Common Stock | +16,000 | $8.04 | $129k | 62,444 | Nov 27, 2024 |
| Nov 27, 2024 | SOpen-market sale Common Stock | -16,000 | $44.83 | $717k | 46,444 | Nov 27, 2024 |
| Nov 26, 2024 | MOption exercise Stock Option (right to buy)derivative | -5,529 | $0.00 | $0 | 121,971 | Nov 27, 2024 |
| Nov 27, 2024 | MOption exercise Stock Option (right to buy)derivative | -10,000 | $0.00 | $0 | 111,971 | Nov 27, 2024 |
| Nov 27, 2024 | MOption exercise Stock Option (right to buy)derivative | -16,000 | $0.00 | $0 | 95,971 | Nov 27, 2024 |
Related signals
Other insiders at Protagonist Therapeutics, Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $8.3M 58,629 shares | -50% | |
| 20Weak | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $18M 125,000 shares | -22% | |
| 42Moderate | PTGXsell Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $2.6M 24,765 shares | -29% | |
| 42Moderate | PTGXsell Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $3.8M 46,203 shares | -43% | |
| 43Moderate | PTGXsell Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $708k 8,588 shares | -10% | |
| 28Weak | PTGXsell Protagonist Therapeutics, Inc | Arturo Molina Md Chief Medical Officer | $230k 2,712 shares | -3% | |
| 25Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $979k 12,000 shares | -70% | |
| 18Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $257k 4,000 shares | -44% | |
| 18Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $237k 4,000 shares | -30% | |
| 44Moderate | PTGXsell Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $571k 10,415 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.